We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
Read MoreHide Full Article
Key Takeaways
Tempus AI's Q2 2025 net loss improved to $42.8M from $509.4M in Q2 2024.
TEM's revenues grew 89.6% y/y to $314.6M, led by 115% growth in genomics sales.
TEM's gross profit surged 160% y/y to $195M, supported by higher-margin products.
Tempus AI (TEM - Free Report) reported an improvement in net loss of $42.8 million in the second quarter of 2025 compared with the year-ago quarter’s net loss of $552.2 million. The company highlighted several operational and financial improvements that collectively drove this huge narrowing of net loss.
Total revenues surged 89.6% year over year to $314.6 million, supported by exceptional performance across its business segments. Genomics revenues soared 115% to $241.8 million, while Data and Services revenues increased 35.7% year over year to $73 million.
Additionally, second-quarter gross profit rose sharply to $195 million, approximately a 160% year-over-year increase, reflecting improved cost management and a shift toward higher-margin products. Operational efficiency also improved significantly, with adjusted EBITDA narrowing from a negative $16 million in first-quarter 2025 to a negative $5.6 million in second-quarter 2025, demonstrating stronger cost discipline and operational leverage as the company scaled.
Just after quarter end, Tempus AI completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing its balance sheet and allowing it to replace a portion of the existing term loan with a significantly lower interest debt instrument. Although this refinancing occurred post-quarter, it highlights the company’s commitment to lowering non-operational costs and enhancing financial stability. Meanwhile, TEM ended the quarter with $293.0 million in cash and marketable securities, an improvement of approximately $70 million over last quarter.
Peer Updates
Guardant Health (GH - Free Report) reported a net loss of $99.9 million for the second quarter of 2025, an improvement of $2.7 million from the year-ago period. This improvement was driven by strong top-line growth of 31% year over year. Guardant Health also saw significant gross margin expansion, fueled by higher oncology average selling prices. In line with this, Guardant360 Tissue’s average selling price increased to approximately $2,000, achieving the 2028 target three years ahead of schedule. Another key factor was the turnaround in Shield and Reveal, both of which moved from negative gross margins in second-quarter 2024 to positive in second-quarter 2025.
Exact Sciences (EXAS - Free Report) reported a net loss of $1.19 million, an improvement of $14.6 million from the year-ago period. This performance was driven by strong total revenue growth of 16% on a reported and core revenue basis. Exact Sciences’ quarterly gross profit rose 15.2% year over year to $562.5 million. Adjusted EBITDA hit a record $138 million. The company’s strong solvency position also contributed to the net loss improvement. In line with this, Exact Sciences exited the second quarter of 2025 with cash, cash equivalents, and marketable securities of $858 million and zero current debt.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have rallied 41.3%, outperforming the industry’s 17% growth and the S&P 500 composite’s 17.4% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.28X compared with the industry average of 5.83X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has moved south by 3%.
Image: Bigstock
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
Key Takeaways
Tempus AI (TEM - Free Report) reported an improvement in net loss of $42.8 million in the second quarter of 2025 compared with the year-ago quarter’s net loss of $552.2 million. The company highlighted several operational and financial improvements that collectively drove this huge narrowing of net loss.
Total revenues surged 89.6% year over year to $314.6 million, supported by exceptional performance across its business segments. Genomics revenues soared 115% to $241.8 million, while Data and Services revenues increased 35.7% year over year to $73 million.
Additionally, second-quarter gross profit rose sharply to $195 million, approximately a 160% year-over-year increase, reflecting improved cost management and a shift toward higher-margin products. Operational efficiency also improved significantly, with adjusted EBITDA narrowing from a negative $16 million in first-quarter 2025 to a negative $5.6 million in second-quarter 2025, demonstrating stronger cost discipline and operational leverage as the company scaled.
Just after quarter end, Tempus AI completed an upsized offering of $750 million 0.75% convertible senior notes, enhancing its balance sheet and allowing it to replace a portion of the existing term loan with a significantly lower interest debt instrument. Although this refinancing occurred post-quarter, it highlights the company’s commitment to lowering non-operational costs and enhancing financial stability. Meanwhile, TEM ended the quarter with $293.0 million in cash and marketable securities, an improvement of approximately $70 million over last quarter.
Peer Updates
Guardant Health (GH - Free Report) reported a net loss of $99.9 million for the second quarter of 2025, an improvement of $2.7 million from the year-ago period. This improvement was driven by strong top-line growth of 31% year over year. Guardant Health also saw significant gross margin expansion, fueled by higher oncology average selling prices. In line with this, Guardant360 Tissue’s average selling price increased to approximately $2,000, achieving the 2028 target three years ahead of schedule. Another key factor was the turnaround in Shield and Reveal, both of which moved from negative gross margins in second-quarter 2024 to positive in second-quarter 2025.
Exact Sciences (EXAS - Free Report) reported a net loss of $1.19 million, an improvement of $14.6 million from the year-ago period. This performance was driven by strong total revenue growth of 16% on a reported and core revenue basis. Exact Sciences’ quarterly gross profit rose 15.2% year over year to $562.5 million. Adjusted EBITDA hit a record $138 million. The company’s strong solvency position also contributed to the net loss improvement. In line with this, Exact Sciences exited the second quarter of 2025 with cash, cash equivalents, and marketable securities of $858 million and zero current debt.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have rallied 41.3%, outperforming the industry’s 17% growth and the S&P 500 composite’s 17.4% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.28X compared with the industry average of 5.83X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has moved south by 3%.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.